Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06289582

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

The overall goal of this protocol is to investigate [18F]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in [18F]DPA-714 binding in PD participants during a 24-month interval.

Primary Objectives

* To compare [18F]DPA-714 binding in prodromal and manifest PD and healthy volunteers. * To determine the longitudinal change in [18F]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants.

Secondary Objectives

* To evaluate the correlation between baseline [18F]DPA-714 and PPMI clinical and biomarker outcomes. * To evaluate the correlation between the longitudinal change of [18F]DPA-714 and PPMI clinical and biomarker outcomes * To acquire safety data following injection of [18F]DPA-714

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

UAB

Birmingham, Alabama, 35294, United States

Location status: Recruiting

Location contact

Evan Hudson, BS

CONTACT

[email protected]

205-934-6499

Jonathan McConathy, MD,PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A prodromal PD and Healthy participant enrolled in PPMI Clinical protocol
  • A PD participant enrolled in PPMI Clinical protocol who has not started symptomatic treatment at time of enrollment or in the first 2 years of participation.
  • Able to provide informed consent
  • Must have screening genetic testing documenting high binder at the at the known TSPO gene polymorphism (rs6971)
  • Male or Female (Females must meet additional criteria specified below, as applicable)
  • Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of [18F]DPA-714
  • Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).
  • Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
  • Females of childbearing potential must not be pregnant, breastfeeding or lactating.
  • Includes a negative urine pregnancy test prior to injection of [18F]DPA-714 on day of PET scan.

Exclusion criteria

  • Exposure to a total effective dose equivalent of 50 millisievert (mSv) for the whole body, which is the annual limit established by the US Code of Federal Regulations , during the past year.
  • Any other medical or psychiatric condition or lab abnormality, which in the opinion of the Site Investigator might preclude participation.

Treatment and study plan

[F-18]DPA714 administration IV

Drug

brain PET/MRI imaging after [F-18]DPA-714 administration

Primary outcomes

  1. Measure baseline and follow up regional brain TSPO levels using [18F]DPA-714-PET in prodromal PD.

    Time frame: 24 months

    The changes over time in neuroinflammation based on TSPO will be assessed by comparing TSPO-PET imaging at baseline, 12 months and 24 months after enrollment.

Study contacts

Contact information is provided by the study sponsor or research team.

Evan Hudson

CONTACT

[email protected]

205-934-6499

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

Registry information

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Mar 4, 2024
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.